MP32-13 INTRA-INDIVIDUAL VARIATIONS IN SERUM TOTAL TESTOSTERONE AMONG MEN PRESENTING FOR EVALUATION OF HYPOGONADISM

INTRODUCTION AND OBJECTIVES: To analyse the metabolic effects of restoring testosterone in obese hypogonadal men all of whom had completed five years of treatment. METHODS: Prospective, registry study of 261 men (mean age: 59.55 8.37 years (32-84 years) with erectile dysfunction and testosterone lower12 nmol/L.164 men completed five years of treatment with parenteral testosterone undecanoate 1000 mg quarterly for 5 years. RESULTS: Weight decreased from 104.23 13.88 (74 e 41kg) to 92.49 11.15 (67-124kg), with statistical significance vs baseline (p<0.0001) and each year compared to the previous year (p<0.0001). Mean change was 11.66 0.43kg or 10.81 0.37%. After five years, 96.3% of men had lost any weight, 80.2% had lost 5 kg, 51.2% 10 kg, 31.5% 15 kg, and 14.2% 20 kg. 3.7% of subjects had gained weight. Waist circumference (cm) decreased from 108.61 10.13 (88-148) to 99.03 9.05 (85-137). The mean change from baseline was 9.56 0.29 cm. BMI decreased from 33.17 4.28 (23.67 43.10) to 29.44 3.37 (19.58 37.39) with statistical significance vs baseline (p<0.0001) and each year compared to the previous year (p<0.0001). Fasting glucose decreased from 112.77 35.87 to 99.02 18.1 mg/dl, HbA1c from 6.73 1.27 to 5.63 0.64%. Total cholesterol declined from 264.24 49.16 to 212.2 40.88, LDL from 162.31 26.28 to 126.41 33.7, triglycerides from 261.07 89.16 to 199.04 52.34 mg/dl. HDL increased from 40.15 13.04 to 55.62 14.66 mg/dl (p<0.0001 vs. baseline for all). Systolicbloodpressuredecreased from140.01 13.61 to 122.35 5.96 mmHg, diastolic blood pressure from 81.67 9.55 to 77.68 4.07 mmHg (p<0.0001 for all). CONCLUSIONS: Testosterone treatment therapy (TRT) for 5 years produced weight loss and improved all parameters of the metabolic syndrome. Reductions in weight and waist circumference were progressive over the full study period.